PCM
MGNX icon

Prelude Capital Management’s MacroGenics MGNX Stock Holding History

Prelude Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$6K – 2162
2020
Q2 		$6K Buy
+200
New +$3.47K ﹤0.01% 1680

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's MGNX Position: Q3 2024 in Review

Prelude Capital Management sold out of MacroGenics (MGNX) in Q3 2024, closing a stake of 14,334 shares — an estimated $60.9K sold.

Prelude Capital Management first reported a position in MGNX in Q4 2014 and held it in 20 quarters. The position peaked at $291K in Q4 2023. 124 funds tracked by Wall St. Rank hold MGNX as of Q3 2024.

  • Prelude Capital Management reported no remaining MacroGenics position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 14,334 MacroGenics shares in Q3 2024, an estimated $60.9K.
  • Prelude Capital Management first reported a position in MacroGenics in Q4 2014 and held it in 20 quarters.
  • Prelude Capital Management's MacroGenics position peaked at $291K in Q4 2023.
  • 124 funds tracked by Wall St. Rank held MacroGenics as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.